Drug Trial Radar · NCT07446049
A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
May 1, 2026
Primary completion
Jan 9, 2028
Study completion Apr 8, 2028
Sponsor
- Lead sponsor
- Convalife (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open-label, multicenter, Phase Ib/II clinical trial of CVL237 tablets in combination with serplulimab injection for the treatment of advanced solid tumors with PTEN loss or low expression
Conditions
- Locally Advanced or Metastatic Solid Tumors
- PTEN Loss or Low Expression
Interventions
CVL237 tabletsDrug
CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary study endpointsTime frame: Up to day 28
- Primary Outcome MeasureTime frame: up to day 28
- Primary Outcome MeasureTime frame: up to day 28
- Primary Study EndpointsTime frame: Up to day 90
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.